TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Colchicine With or Without Stepwise Dose Titration of Febuxostat for Flare Prophylaxis in Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Ages Eligible for Study: more than 20 years~Inclusion Criteria:~1. Hyperuricemia (serum urate ≥7.0 mg/dL and gout by 1977 American College of Rheumatology Criteria~2. Acute gout attack during the last 12 months~Exclusion Criteria:~1. Acute gout attack in the last 2 weeks~2. Urate-lowering therapy in the last 4 weeks~3. Secondary hyperuricemia~4. Creatinine ≥2.0 mg/dL~5. AST or ALT ≥2x upper limits of normal~6. Heart failure (NYHA III-IV)~7. Hypersensitivity to colchicine, NSAID or febuxostat~8. Use of NSAID, glucocorticoid, cyclosporine, clarithromycin, mercaptopurine, azathioprine, pyrazinamide, ethambutol, chemotherapy, tacrolimus, losartan, and fenofibrate~9. Inability to comply with the protocol requirements~10. The judgement of the investigator that the patient was not an appropriate candidate

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Dose titration group (Type: EXPERIMENTAL): Stepwise dose titration of febuxostat and low-dose colchicine
- Standard treatment group (Type: ACTIVE_COMPARATOR): Fixed dose febuxostat and low-dose colchicine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with cancers of the gastrointestinal tract (eg. colorectal, gastric, pancreatic, esophageal)~* Lower age limit: 18; Upper age limit: None~GENDER CRITERIA: None~RACIAL CRITERIA: None~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GI Cancer (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* severe alcohol use disorder according to DSM 5 and heavy drinking: alcohol consumption \>=60g (men) and \>=40g (women) (minimum of 5 days / week)~* right-handedness~* normal or corrected to normal vision~* signed written informed consent~Exclusion Criteria:~valid at the time of MRI investigation:~* psychotropic medication within the last 14 days~* severe withdrawal symptoms (CIWA-Ar \> 4; Sullivan et al. 1989)~* intoxication (breath alcohol concentration \> 0.3 ‰)~* common exclusion criteria for MRI (e.g. metal, claustrophobia)~* positive drug screening (opioids, cannabinoids, benzodiazepines, barbiturates, cocaine, amphetamines)~* pregnancy~* contraindications to the prescription of nalmefene valid at inclusion:~* previous severe withdrawal / withdrawal complications~* previous inpatient detoxification treatment~* other Axis I psychiatric diagnoses than alcohol- or nicotine-dependence in the last 12 months~* neurological disorders, history of brain injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Nalmefene Challenge (Type: EXPERIMENTAL): Participants will receive 18mg Nalmefene two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive Placebo two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Well-demarcated area of GA secondary to AMD~* Women of childbearing potential and men must agree to use adequate contraception for at least 30 days after fluorescein dye administration~* The study is recruiting participants in two different cohorts:~Cohort 1: Participants with unilateral GA OR Cohort 2: Participants with GA in one eye and CNV (active or treated) with or without GA, in the contralateral eye~Exclusion Criteria:~* Previous participation in any studies of investigational drugs for GA / dry AMD (exception for studies of vitamins and minerals)~* GA in either eye due to causes other than AMD~* History of vitrectomy surgery, submacular surgery, or any surgical intervention for AMD~* Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and/or proliferative diabetic retinopathy~* Any ocular/systemic medical conditions that, in the opinion of the investigator, could contribute to participant's inability to participate in the study or interfere with study assessments.~* Requirement for continuous use of therapy indicated in Prohibited Therapy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Geographic Atrophy Participants (Type: None): Participants with unilateral GA or GA in one eye and choroidal neovascularization (CNV; active or treated) with or without GA, in the contralateral eye, will be evaluated for the progression of GA for up to approximately 60 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Study of SNX-5422 in TP53 Null Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed solid or hematological TP53 null type cancer.~* No more than 4 prior lines of systemic anti-cancer therapy.~* Males or non-pregnant, non-breastfeeding females 18 years-of-age or older.~* Karnofsky performance score 60~* Life expectancy of at least 3 months.~* Adequate baseline laboratory assessments~* Recovered from toxicities of previous anticancer therapy to CTCAE Grade ≤ 1 with the exception of alopecia.~Exclusion Criteria:~* Treatment with an investigational agent within 30 days prior to the first dose of SNX-5422 or planning to receive an investigational agent during the study.~* Treatment with other anticancer drugs within 28 days or 5 half-lives of anticancer therapy (whichever is shorter) is prohibited from 30 days prior to the first dose of SNX-5422 and throughout the study.~* Radiation treatment within 2 weeks.~* The need for treatment with medications with clinically relevant metabolism by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422 (Appendix B).~* Appropriately corrected screening ECG QTc interval 470 msec for females, 450 msec for males.~* Currently receiving medications known to cause QT prolongation AND corrected QTc of 450 msec for females, 430 msec for males.~* Patients with chronic diarrhea of grade 2 or greater despite maximal medical management.~* Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.~* Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.~* History of documented adrenal dysfunction not due to malignancy.~* Seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).~* History of chronic liver disease.~* Active hepatitis A or B.~* Current alcohol dependence or drug abuse.~* Clinically significant glaucoma, retinitis pigmentosa, or macular degeneration.~* Other serious concurrent illness or medical condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SNX-5422 (Type: EXPERIMENTAL): Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7-day drug-free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ADEQUATE Advanced Diagnostics for Enhanced Quality of Antibiotic Prescription

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults (≥18 years old) presenting to the Emergency Room with an acute illness (present for 14 days or less) with cough, and with at least 1 other lower respiratory tract symptom or clinical sign at physical examination:~   * Sputum production,~  * Breathlessness,~  * Chest discomfort or chest pain,~  * Wheeze,~  * Crackles,~  * Self-reported dystermia or documented fever;~  * Documented hypoxemia (adjusting definition for chronic oxygen therapy users, method of measurement) and no alternative explanation (infection, such as sinusitis; other, such as asthma).~     2. Managing medical team considers:~    1. to treat patient with antibiotics and/or to hospitalize patient~        AND~    2. that the rapid syndromic diagnostic test result can be awaited up to a maximum of 4 hours before the decision to discharge the patient or to initiate antibiotic therapy.~Exclusion Criteria:~1. Development of ARTI more than 48 hours after hospital admission (hospital acquired);~2. Patients with cystic fibrosis;~3. Less than 14 days since the last episode of respiratory tract infection;~4. Pregnancy (confirmed by pregnancy test) and breastfeeding;~5. Any clinically significant abnormality identified at the time of screening that in the judgment of the Investigator would preclude safe completion of the study or constrain endpoints assessment such as major systemic diseases or patients with short life expectancy;~6. Inability to obtain informed consent from a competent patient.~   Based on standard of care microbiological diagnosis and thoracic imaging (when indicated):~7. Radiologically confirmed acute lobar pneumonia;~8. Known or suspected Pneumocystis jirovecii pneumonia or active tuberculosis;~9. Alternative noninfectious diagnosis that explains clinical symptoms (pulmonary embolism, alveolar hemorrhage, acute heart failure, lung cancer).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Diagnostic intervention
- Standard of Care (Type: NO_INTERVENTION): Standard of care testing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Hip Fracture Discrimination With Quantitative Computed Tomography (QCT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Selection of cases: women with hip fracture~* woman aged 60 years and more~* clinical suspicion of osteoporosis based on the following: trivial trauma (fall from the standing position), history of vertebral fracture or visualization of a vertebral fracture by CT~* availability of radiographs of the proximal femur (anteroposterior view of the pelvis mandatory; anteroposterior and lateral views of the fractured hip optional)~* signature by the patient of the informed consent document~Exclusion criteria:~* patient under 60 years~* current bisphosphonate, oestrogen, or SERM treatment started more than 3 months earlier; or past treatment with these medications stopped less than 6 months earlier~* hip arthroplasty on the other side~* fracture at the site of a bone lesion~* psychiatric disorder that might prevent the patient from giving informed consent or from remaining completely still for about 15 minutes during the investigations~* informed consent document not signed by the patient~Selection of controls:~The controls will be women without hip fracture matched on age to the cases.~Inclusion criteria:~* woman aged 60 years and more~* signature by the patient of the informed consent document~Exclusion criteria:~* age under 60 years~* male~* current bisphosphonate, oestrogen, or SERM therapy started more than 3 months earlier; or past treatment with these medications stopped less than 6 months earlier~* history of osteoporotic hip fracture.~* psychiatric disorder that might prevent the patient from giving informed consent or from remaining completely still for about 15 minutes during the investigations~* informed consent document not signed by the patient

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: None): Women without hip fracture, matched on age to the cases
- Patient (Type: None): Female patients aged 60 and older with hip fracture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pronostic Value of Endothelial Dysfunction in Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients hospitalized for acute heart fialure with Left Ventricular Ejection Fraction (LVEF) \< 45 % on echocardiography~Exclusion Criteria:~* Informed consent form not signed~* Cardiogenic, septic or hemorragic shock~* Acute coronary syndrom with elevated troponin~* valvular surgery or aorto-coronary graft during next 3 months~* Cancer~* Pregnancy~* life expectancy over than 1 year~* chronic renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of GLP-1 for Diabetic Bariatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Candidates for Roux-en-Y Gastric Bypass Surgery with an established diagnosis of Type 2 diabetes requiring insulin treatment for glycemic control~2. Ability to provide informed consent before any trial-related activities~Exclusion Criteria:~1. Prior metabolic surgery procedure~2. Use of GLP-1 analogues for diabetes treatment at the time of recruitment~3. Known or suspected allergy to semaglutide or the excipients in semaglutide, or related products.~4. Contraindications to semaglutide which include a personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia syndrome-2 (MEN-2)~5. Previously randomized for participation in this trial.~6. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures.~7. Type 1 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: PLACEBO_COMPARATOR): Once weekly injection of placebo 4-6 months at prescribed dose
- Test Arm (Type: ACTIVE_COMPARATOR): Once weekly injection of 1.0mg Semaglutide 4-6 months at prescribed dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically and biochemically confirmed recurrent or progressing multiple myeloma that is unlikely to respond to existing therapy, including surgery, radiotherapy, and chemotherapy~  * At least one standard first line therapy failure~* No localized plasmacytoma or plasmacytosis limited to the bone marrow~* Evidence of tumor by MRI or CT scan~* Presence of myeloma proteins in serum and urine, including Bence-Jones proteins~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~* No hepatic insufficiency~Renal:~* Creatinine no greater than 2.5 mg/dL~* No renal problems~* No renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No chronic heart failure~* No uncontrolled hypertension~* No history of congestive heart failure~* No other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study~* No serious medical or psychiatric disorders~* No active infections~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered (patients with multiple tumors who have received radiotherapy to some, but not all, tumors may be admitted earlier than 8 weeks)~Surgery:~* Must be recovered from prior surgery~Other:~* Prior cytodifferentiating agent allowed~* No prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Autologous EBV-specific Cytotoxic T Cells for the Treatment of Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 4 systemic lupus criteria of the American College of Rheumatology with antinuclear antibodies\> 1:80~* Age greater than or equal to 18 years~* Lupus serologically active without active serious disease (Kidney, CNS)~* Anti-native DNA Ac positive and / or C3 or C4 low~* SLEDAI greater than or equal to 2 at baseline~* Serology HBV, HCV, HIV, HTLV-1, syphilis: Negative J-30 before sample~* Hemoglobin \>11g/dL~* Prednisone dose \<15 mg / day with a stable dose within 30 days previous injection~* Immunosuppressive treatments which dosage has not been increased for at least 3 months before enrollment~* Agreement telephone and / or mail for coordinating investigator inclusion~* Social ensured Patient~* EBV positive serology~Exclusion Criteria:~* Evolving severe lupus, requiring high dose corticosteroids and / or immunosuppressive therapy~* Psychiatric disorders~* Predicted Failure to monitoring compliance with impossibility~* Infectious Episode underway~* Evolutionary Cancer~* Risk of death within 6 months~* Consent Refusal~* Pregnancy~* Nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autologous EBV specific CTL infusion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues